Efficacy and Safety of Tofacitinib in Anti–Melanoma Differentiation–Associated 5 Gene Antibody–Positive Dermatomyositis

Abstract

Tofacitinib can be used as a potential therapeutic option for MDA5 + DM. The occurrence of infection requires special attention during treatment, particularly in patients with older age and C-reactive protein levels close to the upper value in reference range.